Thursday, 27 Feb 2020

You are here

Surviving Infection on DMARDs or Biologics

Sepsis is a dangerous and potentially fatal consequence of serious infections (SIE), particularly in susceptible populations such as the elderly and immunosuppressed. Published evidence points toward the potential role of TNF in development of sepsis. Given the broad use of multiple biologic and conventional DMARDs in the treatment of RA, there is a need to understand the impact of our current treatments on SIE outcomes.

This cohort study assessed patients with RA who acquired SIE after enrollment into the German biologics register RABBIT (Rheumatoid arthritis: observation of biologic therapy). The contribution of RA treatment and patient characteristics to the three different outcomes of SIE was examined and the overall risk of death within 90 days after the onset of SIE was investigated.

Among all 1017 SIEs, pneumonia was most frequent (n=332; 28.4%), followed by 131 infections of bones and joints (11.2%) and 120 respiratory infections other than pneumonia (10.3%). No difference in the spectrum of SIEs was observed between bDMARDs vs csDMARDs groups. Sepsis within 30 days after SIE was reported in 135 out of 947 patients, 85 of these had a fatal outcome.

Death within 90 days after SIE (without known sepsis) occurred in 53 patients. Compared with conventional synthetic DMARDs (csDMARDs), the risk of death was significantly lower when patients were exposed to biologic DMARDs (bDMARDs) at the time of SIE (OR: 0.56, 95% CI 0.38 to 0.81). Risk factors of fatal SIE were higher age, use of glucocorticoids at higher doses and heart failure.

These study results suggest that patients exposed to bDMARDs at the time of SIE have a reduced risk of sepsis and mortality. This study is a first-report of reduced sepsis risk in patients with RA on bDMARDs. Although being off bDMARDs seems to shift the risk from an increased susceptibility to SIE to more severe outcomes, the authors do not recommend that bDMARDs be continued in case of an SIE since this is the first study to show these results. Additional studies and data are needed to answer the question of drug management in the face of infection.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Overmedication of America

Recent research from the Lown Institute reports that 750 older Americans are hospitalized daily because of serious side effects from and the core problem is that of polypharmacy, especially in the elderly. 

Best of 2019 - Biologic Safety Guidelines from the British Society for Rheumatology

In the United Kingdom, NICE has looked to the British Society of Rheumatology (BSR) to develop evidence based guidance on the safe use of biologic DMARDs in patients with inflammatory arthritis. This guidance document on biologic safety covers baseline screening, monitoring, effect of co-morbidities, and when or under what circumstances biologic therapy should be interrupted.

Best of 2019 - Methotrexate and the Risk of Lung Disease

Rheumatology has a comprehensive overview of methotrexate (MTX) and the risk of lung injury, MTX-related pneumonitis and interstitial lung disease (RA-ILD) with rheumatoid arthritis (RA). Past reports suggest the frequence of MTX-pneumonitis to be between 0.3 and 11.6%; recent studies suggest it may be much lower.

No Cancer Risk with Systemic Necrotizing Vasculitis

The French Vasculitis Study Group has published that patients with systemic necrotizing vasculitis do not have an increased risk of malignancy; in fact they have a risk that is similar to the general population.

Previous reports have suggested either no risk or a declining risk in the era of better therapies for vasculitis. 

FDA Warns 15 CBD Manufacturers

Today, the U.S. Food and Drug Administration issued warning letters to 15 companies for illegally selling products containing cannabidiol (CBD) in ways that violate the Federal Food, Drug, and Cosmetic Act (FD&C Act).  This warning affirms that the FDA has not determined the many preparations of cannabidiol to be safe or effective.